Obesity companies may need to double the size of their Phase II and III programs if FDA follows a panel's recommendation to hold obesity drugs to the same standard as diabetes drugs in terms of preapproval cardiovascular risk assessment. Since FDA issued its final guidance for assessing the CV risk for diabetes drugs in 2008, the designs of Phase II and Phase